Mineralocorticoid Receptor Antagonists (Spironolactone)
Treatment for Heart Failure
Typical Dosage: 12.5 mg daily up to 25-50 mg daily
Effectiveness
77%
Safety Score
70%
Clinical Trials
10
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
12.5 mg daily up to 25-50 mg daily
Time to Effect
1-3 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
16(Treat 16 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180
Monitoring:$900
Side Effect Mgmt:$150
Total Annual:$1,230
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$8,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$3,514
Comparison vs No treatment
Cost Difference
$-500/year
Less expensive
QALY Difference
+0.40 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Mineralocorticoid Receptor Antagonists (Spironolactone) Outcomes
for Heart Failure
Efficacy Outcomes
Overall Effectiveness
+77%
Response Rate
+35%
Common Side Effects
Hyperkalemia
+8%
Gynecomastia
+12%
Renal impairment
+4%
Sources:
Active Clinical Trials
2 active trials recruiting for Mineralocorticoid Receptor Antagonists (Spironolactone) in Heart Failure
Therapy to Maintain Remission in Dilated Cardiomyopathy
NCT06091475RECRUITINGNA
50 participants
INTERVENTIONAL
London, United Kingdom
Started: Dec 2, 2023
Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)
NCT07304817NOT YET RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Groningen, Netherlands +1 more
Started: Feb 1, 2026
Completed Clinical Trials
8 completed trials for Mineralocorticoid Receptor Antagonists (Spironolactone) in Heart Failure
Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance
NCT02585843COMPLETEDPHASE2, PHASE3
20 participants
INTERVENTIONAL
New York, United States
Started: Nov 1, 2015
Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
NCT01691053COMPLETEDPHASE2
118 participants
INTERVENTIONAL
Erlangen, Germany +2 more
Started: Dec 1, 2012
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
NCT00094302COMPLETEDPHASE3
3.44K participants
INTERVENTIONAL
Birmingham, United States +269 more
Started: Aug 1, 2006
Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
NCT04575675COMPLETEDPHASE4
78 participants
INTERVENTIONAL
Taipei, Taiwan
Started: May 29, 2020
Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients
NCT02200822COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Genk, Belgium
Started: Jul 1, 2014
Polypill Strategy for Heart Failure With Reduced Ejection Fraction
NCT04633005COMPLETEDPHASE2
212 participants
INTERVENTIONAL
Dallas, United States
Started: Nov 15, 2021
Spironolactone Therapy in Chronic Stable Right HF Trial
NCT03344159COMPLETEDPHASE4
15 participants
INTERVENTIONAL
Ottawa, Canada
Started: Apr 1, 2018
Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment
NCT05411991COMPLETEDPHASE4
107 participants
INTERVENTIONAL
Jette, Belgium +1 more
Started: Jun 12, 2022